全文获取类型
收费全文 | 21031篇 |
免费 | 2107篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 294篇 |
儿科学 | 748篇 |
妇产科学 | 620篇 |
基础医学 | 2979篇 |
口腔科学 | 616篇 |
临床医学 | 2819篇 |
内科学 | 3799篇 |
皮肤病学 | 365篇 |
神经病学 | 1834篇 |
特种医学 | 756篇 |
外科学 | 2443篇 |
综合类 | 513篇 |
一般理论 | 12篇 |
预防医学 | 2260篇 |
眼科学 | 291篇 |
药学 | 1668篇 |
中国医学 | 25篇 |
肿瘤学 | 1134篇 |
出版年
2021年 | 296篇 |
2020年 | 205篇 |
2019年 | 350篇 |
2018年 | 398篇 |
2017年 | 301篇 |
2016年 | 332篇 |
2015年 | 366篇 |
2014年 | 490篇 |
2013年 | 737篇 |
2012年 | 966篇 |
2011年 | 1018篇 |
2010年 | 656篇 |
2009年 | 556篇 |
2008年 | 1006篇 |
2007年 | 995篇 |
2006年 | 1026篇 |
2005年 | 892篇 |
2004年 | 861篇 |
2003年 | 757篇 |
2002年 | 788篇 |
2001年 | 637篇 |
2000年 | 662篇 |
1999年 | 531篇 |
1998年 | 249篇 |
1997年 | 189篇 |
1996年 | 203篇 |
1995年 | 215篇 |
1994年 | 193篇 |
1993年 | 218篇 |
1992年 | 458篇 |
1991年 | 430篇 |
1990年 | 425篇 |
1989年 | 444篇 |
1988年 | 429篇 |
1987年 | 337篇 |
1986年 | 359篇 |
1985年 | 394篇 |
1984年 | 271篇 |
1983年 | 217篇 |
1982年 | 163篇 |
1981年 | 165篇 |
1979年 | 214篇 |
1978年 | 190篇 |
1977年 | 200篇 |
1976年 | 171篇 |
1975年 | 165篇 |
1974年 | 172篇 |
1973年 | 181篇 |
1972年 | 169篇 |
1971年 | 163篇 |
排序方式: 共有10000条查询结果,搜索用时 65 毫秒
1.
Robinson Sandra M. Scott Jason Ryan Sarah Adams Nicola Hassell Andrew Walker David 《Clinical rheumatology》2022,41(12):3869-3877
Clinical Rheumatology - Educating patients about methotrexate is a core role of rheumatology nurses. We have previously reported the scoring of videoed interviews of rheumatology nurses educating... 相似文献
2.
Maternal and Child Health Journal - In Virginia, Black women experience higher rates of adverse birth and labor outcomes that may not be explained solely by risky behaviors or social standing.... 相似文献
3.
4.
Phantana-angkool April Voci Amy E. Warren Yancey E. Livasy Chad A. Beasley Lakesha M. Robinson Myra M. Hadzikadic-Gusic Lejla Sarantou Terry Forster Meghan R. Sarma Deba White Richard L. 《Annals of surgical oncology》2019,26(12):3874-3882
Annals of Surgical Oncology - The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Our aim was to assess... 相似文献
5.
6.
Rosemary Frey Deborah Balmer Jackie Robinson Merryn Gott Michal Boyd 《Journal of pain and symptom management》2019,57(3):545-555.e1
Context
In most resource-rich countries, a large and growing proportion of older adults with complex needs will die while in a residential aged care (RAC) facility.Objectives
This study describes the impact of facility size (small/large), ownership model (profit/nonprofit) and provider (independent/chain) on resident comfort, and symptom management as reported by RAC staff.Methods
This retrospective “after-death” study collected decedent resident data from a subsample of 51 hospital-level RAC facilities in New Zealand. Symptom Management at the End-of-Life in Dementia and Comfort Assessment in Dying at End of life with Dementia (SM-EOLD and CAD-EOLD, respectively) scales were used by RAC staff who were closely associated with 217 deceased residents. Data collection occurred from January 2016 to February 2017.Results
Results indicated that residents of large, nonprofit facilities experienced greater comfort at the end of life (CAD-EOLD) as indicated by a higher mean score of 37.21 (SD = 4.85, 95% CI = 34.4, 40.0) than residents of small for-profit facilities who recorded a lower mean score of 31.56 (SD = 6.20, 95% CI = 29.6, 33.4). There was also evidence of better symptom management for residents of chain facilities, with a higher mean score for symptom management (SM-EOLD total score) recorded for residents of chain facilities (mean = 28.07, SD = 7.64, 95% CI = 26.47, 29.66) than the mean score for independent facilities (mean = 23.93, SD = 8.72, 95% CI = 21.65, 26.20).Conclusion
Findings suggest that there are differences in the quality of end-of-life care given in RAC based on size, ownership model, and chain affiliation. 相似文献7.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
8.
9.
Johnson Courtney A. Tran Dan N. Mwangi Ann Sosa-Rub Sandra G. Chivardi Carlos Romero-Martnez Martn Pastakia Sonak Robinson Elisha Jennings Mayo-Wilson Larissa Galrraga Omar 《Health services & outcomes research methodology》2022,22(3):297-316
Health Services and Outcomes Research Methodology - To slow the spread of COVID-19, most countries implemented stay-at-home orders, social distancing, and other nonpharmaceutical mitigation... 相似文献
10.